Skip to content
Denis Chem Lab logo

Denis Chem Lab

537536 BSE
₹60.01

Close ·

P/E
10.44
View as Markdown
MCP
Close 4 Nov 2026 ₹60.01 −31.74 −34.6% 1Y
Start ₹91.75

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
14.00%
Debt to Equity
0.04
EPS (TTM)
₹5.75
Book Value
₹65.99
Market Cap
—
P/E (TTM)
10.44
P/B
0.91
ROE
9.52%
Dividend Yield
4.03%
EBITDA
₹19.60 Cr
52W High
₹93.00
52W Low
₹56.10

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

58 Good

Data confidence 100/100

Category scores

Quality
58
Good
Returns, margins, earnings quality 22% weight
Valuation
79
Strong
Cheap vs sector & own history 24% weight
Growth
43
Weak
Sales & profit trajectory 9% weight
Financial Health
75
Strong
Solvency, leverage, coverage 9% weight
Momentum
23
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is almost debt free.
  • Stock is trading at 1.02 times its book value
  • Stock is providing a good dividend yield of 3.70%.
  • Company has been maintaining a healthy dividend payout of 32.7%

Weaknesses

3
  • The company has delivered a poor sales growth of 10.8% over past five years.
  • Promoter holding is low: 39.0%
  • Company has a low return on equity of 11.2% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBullish162
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
35.10
Neutral
MACD (12,26,9)
−1.68
Bullish
SMA (50)
66.93
Bearish
SMA (200)
72.13
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+6.33%
5Y+10.68%
3Y+3.98%
1Y+4.62%
TTM+4.06%

Net profit

Net profit growth by window
10YTurned to profit
5Y+31.95%
3Y0.00%
1Y0.00%
TTM−5.90%

Operating cash flow

Operating cash flow growth by window
10Y−15.28%
5Y−12.94%
3Y−37.00%
1Y−66.67%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+1.78 pp
5Y+0.77 pp
3Y−1.86 pp
1Y+0.69 pp
TTM−0.33 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹112 Cr
Mar 2018₹107 Cr
Mar 2019₹123 Cr
Mar 2020₹135 Cr
Mar 2021₹109 Cr
Mar 2022₹136 Cr
Mar 2023₹161 Cr
Mar 2024₹167 Cr
Mar 2025₹173 Cr
Mar 2026₹181 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1.00 Cr
Mar 2018₹2.00 Cr
Mar 2019₹6.00 Cr
Mar 2020₹4.00 Cr
Mar 2021₹2.00 Cr
Mar 2022₹6.00 Cr
Mar 2023₹8.00 Cr
Mar 2024₹11.00 Cr
Mar 2025₹8.00 Cr
Mar 2026₹8.00 Cr

Quarterly Results

₹ Cr
537536 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
42.48
45.43
40.06
39.85
41.26
47.82
42.84
41.38
43.28
46.17
45.52
46.75
44
Expenses
37.45
40.29
34.07
34.77
36.91
41.94
39.01
39.32
38.46
41.91
39.49
44.21
40.17
Operating Profit
5.03
5.14
5.99
5.08
4.35
5.88
3.83
2.06
4.82
4.26
6.03
2.54
3.83
OPM %
11.84%
11.31%
14.95%
12.75%
10.54%
12.3%
8.94%
4.98%
11.14%
9.23%
13.25%
5.43%
8.7%
Other Income
0.01
0.52
0.26
0.59
0.32
0.58
0.3
1.17
0.3
0.65
0.44
0.54
0.45
Interest
0.09
0.09
0.13
0.23
0.12
0.09
0.07
0.23
0.19
0.23
0.22
0.2
0.11
Depreciation
1.59
1.76
1.84
1.75
1.63
1.66
1.84
1.73
1.61
1.65
1.83
1.74
1.53
PBT
3.36
3.81
4.28
3.69
2.92
4.71
2.22
1.27
3.32
3.03
4.42
1.14
2.64
Tax %
20.24%
33.07%
25.23%
26.02%
28.77%
25.05%
20.72%
44.09%
25.3%
27.06%
24.66%
64.91%
22.73%
Net Profit
2.68
2.54
3.2
2.73
2.08
3.53
1.76
0.71
2.48
2.21
3.32
0.4
2.05
EPS (₹)
1.93
1.83
2.31
1.97
1.5
2.54
1.27
0.51
1.79
1.59
2.39
0.29
1.48

Profit & Loss

₹ Cr
537536 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
75
98
112
107
123
135
109
136
161
167
173
181
182
Expenses
66
89
98
95
110
120
99
122
142
146
157
164
166
Operating Profit
9
8
14
12
14
15
10
14
19
21
16
18
17
OPM %
12%
9%
12%
11%
11%
11%
9%
11%
12%
13%
9%
10%
9%
Other Income
0
0
1
1
2
0
0
1
1
1
2
2
2
Interest
5
7
6
5
3
3
2
1
1
1
1
1
1
Depreciation
4
6
7
6
6
7
6
6
8
7
7
7
7
PBT
0
−3
2
2
6
6
3
9
11
15
11
12
11
Tax %
78%
30%
37%
−5%
−7%
26%
27%
30%
28%
26%
27%
29%
—
Net Profit
0
−4
1
2
6
4
2
6
8
11
8
8
8
EPS (₹)
0.07
−4.16
0.89
1.54
4.58
3.03
1.63
4.51
5.66
8.04
5.82
6.06
5.75
Div. Payout %
0%
0%
0%
0%
22%
0%
46%
33%
35%
31%
26%
41%
—

Balance Sheet

₹ Cr
537536 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
12
14
14
14
14
14
14
14
14
14
Reserves
8
7
18
36
43
45
48
53
58
66
71
78
Borrowings
48
44
37
25
23
14
9
3
2
1
1
4
Other Liabilities
17
24
27
26
26
25
22
27
25
28
26
29
Total Liabilities
81
85
94
101
106
97
92
96
99
109
112
125
Fixed Assets
42
40
44
40
50
46
41
42
35
38
39
37
CWIP
0
10
1
5
0
0
0
0
2
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
39
35
49
56
55
52
51
55
62
72
73
88
Total Assets
81
85
94
101
106
97
92
96
99
109
112
125

Cash Flow

₹ Cr
537536 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
14
21
7
11
8
13
8
17
16
18
12
4
Investing
−28
−13
−1
−16
−2
−2
−1
−10
−11
−15
−8
−5
Financing
13
−7
0
1
−5
−14
−6
−7
−4
−4
−4
0
Net Cash Flow
−1
1
5
−4
1
−3
1
0
1
−1
0
0
Free Cash Flow
−14
8
5
2
−2
11
6
12
12
11
4
−1
CFO/OP
154
246
49
92
65
101
85
126
100
104
105
38

Ratios

537536 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
123
85
104
105
106
94
110
85
71
69
65
78
Inventory Days
40
39
35
52
50
51
60
50
39
43
37
40
Days Payable
81
119
136
150
102
108
103
99
79
90
81
81
Cash Conversion Cycle
81
4
3
8
55
37
67
36
31
22
21
36
Working Capital Days
−19
−57
−13
4
17
32
63
51
41
37
38
50
ROCE %
11%
5%
12%
9%
11%
11%
6%
14%
16%
20%
14%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Denis Chem Lab insights

67 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 38.98%
  • Public 34.90%
  • Others 26.11%
  • FIIs 0.01%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Denis Chem Lab

What does Denis Chem Lab Ltd do?
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles
Where is Denis Chem Lab Ltd (DENISCHEM) listed?
Denis Chem Lab Ltd trades under code 537536 on the BSE.
Which sector does Denis Chem Lab Ltd belong to?
Denis Chem Lab Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Denis Chem Lab Ltd?
Denis Chem Lab Ltd trades at a PE ratio of 10.44 as of 4 Nov 2026, on earnings per share of ₹5.75, against a book value of ₹65.99 per share.
What is the 52-week high and low of Denis Chem Lab Ltd?
Over the last 52 weeks Denis Chem Lab Ltd has traded between ₹56.1 and ₹93 as of 4 Nov 2026.
Does Denis Chem Lab Ltd pay dividends?
Denis Chem Lab Ltd has a dividend yield of 4.03%.
What is the Return on Equity (ROE) of Denis Chem Lab Ltd?
Denis Chem Lab Ltd reported a return on equity of 9.52%. Its debt-to-equity ratio is 0.04.

Company Information

Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles

Website denischemlab.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/537536.md for Denis Chem Lab Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month